REGENHU announces its participation in the FLAMIN-GO project aimed at developing personalized treatments against rheumatoid arthritis
REGENHU today announced its participation in the FLAMIN-GO research project aimed at developing an organ-on-chip technology for clinical trials on Rheumatoid Arthritis (RA).
FLAMIN-GO is an EU-funded project featuring a strong, well-balanced composition of hospital, academia, and industry partners which brings together the know-how of experts in the fields of rheumatology, material science, tissue engineering, nanotechnology, cell biology, and 3D modeling, in a cohesive, transdisciplinary, multi-sectorial approach. The objective is to develop a personalized next-generation synovia-on-chip, that, by effectively mimicking the complexity of an RA joint, will enable personalized clinical trials-on-chip, and ultimately open new avenues toward personalized care in RA.